MedDataX Logo

Silymarin vs Hesperidin/Diosmin in Fibromyalgia

NCT ID: NCT07293767

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-16

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fibromyalgia is a chronic disease, characterized by chronic widespread pain, physical exhaustion, sleep problems, and unexplained pain in both joints and muscles. Fibromyalgia's causes still unknown, but there are various risk factors that can cause fibromyalgia such as genetic causes, physical shock, and infections. Fibromyalgia typically presents in young or middle aged females, it occurs in females more than males, and it is characterized with widespread pain throughout the whole body in both sides such as arms, shoulders, head, and abdominal areas. The etiology of fibromyalgia still unclear, but there are several factors such as alterations in the sleep pattern, changes in the neuroendocrine transmitters such as cortisol, growth hormones and serotonin, dysfunction of central and autonomic nervous systems, psychiatric aspects and external stressors . The pain seems to result from neurochemical imbalances in the central nervous system that lead to a "central amplification" of pain perception characterized by allodynia (a heightened sensitivity to stimuli that are not normally painful) and hyperalgesia (an increased response to painful stimuli). this interventional study aims to study effect of silymarin and hesperidin/diosmin combination on fibromyalgia patients and compare their effect with control patients on the following

1. Management of pain.
2. Inflammatory biomarkers.
3. Quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fibromyalgia is a chronic disease characterized by chronic widespread pain, physical exhaustion, sleep problems, and unexplained pain in joints and muscles. Although the exact causes remain unknown, several risk factors have been implicated, including genetic predisposition, physical or emotional stress, and infections. Fibromyalgia occurs predominantly in females and is associated with widespread pain in multiple body regions such as the arms, shoulders, head, and abdomen. The etiology involves alterations in sleep patterns, changes in neuroendocrine transmitters such as cortisol, growth hormone, and serotonin, along with dysfunction of the central and autonomic nervous systems. Pain is believed to result from neurochemical imbalances that lead to central amplification of pain perception, characterized by allodynia and hyperalgesia.

Diagnosis of fibromyalgia is challenging, as no specific laboratory tests or imaging confirm the condition. The 1990 ACR criteria relied on tender points and widespread pain for at least three months. More recently, the ACR proposed new diagnostic criteria incorporating the Widespread Pain Index (WPI) and Symptom Severity (SS) scale, which evaluate pain in 19 body regions and rate associated symptoms such as fatigue, cognitive difficulties, headache, and dizziness.

Management of fibromyalgia includes several approaches. FDA-approved medications include pregabalin, duloxetine, and milnacipran, although these may be costly and associated with side effects. Anticonvulsants, amitriptyline, and fluoxetine may also be used to improve pain and sleep. Non-pharmacological therapies include biofeedback, cognitive behavioral therapy, physiotherapy, exercise, and electromyogram-guided interventions. Alternative therapies such as acupuncture, chiropractic care, deep tissue massage, neuromuscular massage, meditation, and certain herbal supplements (e.g., echinacea purpurea, black cohosh, lavender, Silybum marianum) have shown varying degrees of benefit.

Inflammatory mediators, particularly IL-6 and IL-8, are commonly elevated in fibromyalgia and correlate with functional impairment, fatigue, and sleep disturbance. Silymarin, extracted from Silybum marianum, possesses hepatoprotective, antioxidant, anti-inflammatory, immunomodulatory, and cardioprotective activities. It has demonstrated reductions in inflammatory cytokines such as TNF-α and IL-6 and showed significant reduction of IL-1α and IL-8 in clinical studies. Diosmin/hesperidin, a flavonoid combination derived from citrus fruits, also exhibits antioxidant and anti-inflammatory activity and has produced antihyperalgesic effects in neuropathic pain models through the reduction of TNF-α, IL-1β, and IL-6.

Based on these findings, the current study hypothesizes that administering silymarin or diosmin/hesperidin in addition to standard fibromyalgia therapy may reduce inflammation and improve pain outcomes in patients with fibromyalgia. The study will compare the effects of silymarin versus diosmin/hesperidin on clinical symptoms, inflammatory biomarkers, and quality of life over a four-month period, as well as evaluate their safety and tolerability.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibromyalgia (FM)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

fibromyalgia silymarin hesperidin diosmin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Group I: 30 patients will receive their standard treatment of fibromyalgia for four months. Group II: 30 patients will receive 500 mg of diosmin/ hesperidine combination under the trade name of daflon with their standard treatment of fibromyalgia for four months. Group III: 30 patients will receive 140 mg of silymarin three times daily under the trade name of Legalon with their standard treatment for four months.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Silymarin group

this group of patients will receive silymarin (LEGALON) 140 mg three times daily with the standard treatment

Group Type EXPERIMENTAL

Silymarin (LEGALON)

Intervention Type DRUG

oral silymarin (legalon) 140 mg will be taken 3 times daily for 12 weeks with the standard treatment

Diosmin/hisperedin group

this group will receive hesperidin/diosmin (daflon) 500 once daily for 12 weeks with the standard treatment

Group Type EXPERIMENTAL

Diosmin / Hesperidin (Daflon)

Intervention Type DRUG

Diosmin / Hesperidin (Daflon) 500 mg will be taken once daily for 12 weeks with the standard treatment

Standard care group

participants will receive standard treatment only

Group Type ACTIVE_COMPARATOR

no intervention (control group)

Intervention Type OTHER

this group will receive no intervention (only the standard treatment)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Silymarin (LEGALON)

oral silymarin (legalon) 140 mg will be taken 3 times daily for 12 weeks with the standard treatment

Intervention Type DRUG

Diosmin / Hesperidin (Daflon)

Diosmin / Hesperidin (Daflon) 500 mg will be taken once daily for 12 weeks with the standard treatment

Intervention Type DRUG

no intervention (control group)

this group will receive no intervention (only the standard treatment)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed written consent.
* Participant must meet the American College of Rheumatology 2016 revised classification criteria for Fibromyalgia: Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5, or WPI 3 to 6 and SS scale score ≥ 9
* Age \>18 years old (males and females)
* Diagnosis of FM confirmed by a rheumatologist.
* Persistent pain syndrome on conventional therapy.
* Not taking Daflon or Legalon for 6 months.

Exclusion Criteria

* Pain due to other conditions (e.g. diabetic peripheral neuropathic pain or post-herpetic neuralgia) that would confound assessment or self-evaluation of the pain associated with FM.
* Patients with pain due to any widespread inflammatory musculoskeletal disorder (e.g. rheumatoid arthritis, lupus) or widespread rheumatic disease other than FM.
* Allergy to silymarin or diosmin or hesperidin.
* Cognitive deficits that could impair understanding of the study, completion of questionnaires, or adherence to therapy.
* Pregnant or planning pregnancy women and breastfeeding women.
* Major comorbidities like renal impairment, severe liver disease, chronic hepatitis C, history of alcohol or drug addiction.
* Current severe or uncontrolled major depressive disorder or anxiety disorders.
* Patients will be excluded if there is no compliance to the medication.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

minna sayed

pharmacist

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Outpatients clinic of department of Internal medicine- Rheumatology unit Ain shams hospitals.

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

menna s teaching assistant of clinical pharmacy/ master's student

Role: CONTACT

Phone: 01064897439

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

mennaallah sayed s teaching assistant of clinical pharmacy/ master's student, master's

Role: primary

nagwa ali A Professor of clinical pharmacy

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FM

Identifier Type: -

Identifier Source: org_study_id